UPDATE 1-Astra-Sanofi’s RSV therapy ‘highly effective’ against infant hospitalizations, CDC study shows

AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a U.S. Centers of Disease Control and Prevention study showed. Early real-world data from the agency's surveillance network showed the therapy nirsevimab's effectiveness in protecting infants against RSV-related hospitalization in their first season of potential exposure to the virus.